Report: Biologics to account for 26% by global pharmaceutical value by 2020
Tuesday, August 1, 2017
Biologics products are likely to account for 26% by value of the global pharmaceutical products by 2020. The Research and Markets report constitutes of an in-depth study of the biologics drug discovery market, including a thorough analysis of the products across different regions.
Biologics involve complex manufacturing procedures and are required to be maintained at pre-determined conditions as they are highly sensitive to changes in ambience. Consequently, companies need to invest huge amounts in terms of capital, to meet the standards, which will eventually increase the cost of biologics.
The introduction of biologic therapies gave a new ray of hope for people suffering from chronic inflammatory diseases. Biologics effected their life not only by reducing dependency on health and welfare systems but also by improving their physical function to live independently. The entry of biosimilars makes these effective therapies more affordable, though the concern of after effects still exists. Some industry experts also express their caution regarding the entry of biosimilars, which might add to the concerns of safety and after effects of the therapies.